Newron Pharmaceuticals S.p.A. NWRN.SW · Stock Open Newron Pharmaceuticals S.p.A. in new tab
Newron Pharmaceuticals S.p.A. Analysis (NWRN.SW)
Is Newron Pharmaceuticals S.p.A. a good investment? Newron Pharmaceuticals S.p.A. (NWRN.SW) is currently trading at 12.74 CHF. Market analysts have a consensus price target of 48.29 CHF. This suggests a potential upside from current levels.
Earnings Schedule: Newron Pharmaceuticals S.p.A. is expected to release its next earnings report on Sept. 22, 2026. The market consensus estimate for Forward EPS is 0.75.
Investor FAQ
Does Newron Pharmaceuticals S.p.A. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Newron Pharmaceuticals S.p.A.?
Newron Pharmaceuticals S.p.A. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Sept. 22, 2026. The company currently has a trailing EPS of -0.62.
Company Profile
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
Community Discussion